Parabilis Medicines, Inc. (NASDAQ:PBLS)
| Market Cap | $3.30B+35.4% |
| Revenue (ttm) | $2.26M |
| Net Income | -$142.27M |
| EPS | -$1.17 |
| Shares Out | 121.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,826.342 |
| Open | $27.63 |
| Previous Close | $27.69 |
| Day's Range | $26.64 - $27.71 |
| 52-Week Range | $20.00 - $42.49 |
| Beta | 5.03 |
| Analysts | n/a |
| Price Target | $40.00(+47.77%) |
| Earnings Date | Mar 3, 2027 |
About PBLS
Parabilis Medicines, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyNext catalysts
- Mar 3, 2027Earnings report
$PBLS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in PBLS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by PBLS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
PBLS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New PBLS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to PBLS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in PBLS
| VTIVanguard Morningstar Total Stock Market ETF | $36.20M |
| IWMiShares Russell 2000 ETF | $30.56M |
| VBVanguard Morningstar Small-Cap ETF | $25.60M |
| VBRVanguard Morningstar Small-Cap Value ETF | $16.65M |
| VXFVanguard Extended Market ETF | $12.89M |
| VTWOVanguard Russell 2000 ETF | $7.43M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from PBLS’s recent data — informational, not investment advice
What’s Behind the Score
News check: None of the provided headlines directly reference PBLS or contain material business news specific to the company.
Recent Insider Activity
Frequently Asked Questions
Upcoming unlocks
ETFs that hold this stock
| PEPT | REX Peptide ETF | 2.72% |
| HLTH | Tema Healthcare AI ETF | 1.98% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.12% |
| FPX | First Trust US Equity Opportunities ETF | 0.11% |
| BKSE | BNY Mellon US Small Cap Core Equity ETF | 0.09% |
| RFLR | Innovator U.S. Small Cap Managed Floor ETF | 0.08% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.05% |
| IWO | iShares Russell 2000 Growth ETF | 0.05% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.03% |
| FBCG | Fidelity Blue Chip Growth ETF | 0.03% |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.01% |
Weight is the stock’s share of each fund’s holdings.